Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
Sponsor: Ansun Biopharma, Inc.
Listed as NCT03808922, this PHASE3 trial focuses on COVID-19 and Immunocompromised and remains actively recruiting participants. Sponsored by Ansun Biopharma, Inc., it has been updated 21 times since 2019, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
21 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Sep 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 16 earlier versions
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jul 2022 — Aug 2023 [monthly]
Recruiting PHASE3
-
Feb 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Apr 2021 — Feb 2022 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
May 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Sep 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Jul 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ansun Biopharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .